Last updated: February 20, 2026
What is the core scope of Denmark patent DK3307271?
Patent DK3307271 relates to a specific pharmaceutical formulation or compound. The scope encompasses the composition, method of manufacturing, and therapeutic use. The patent's claims focus on identifying an innovative aspect of the drug, including specific chemical entities, formulations, delivery forms, or combined therapeutic effects.
The patent is positioned within the sphere of [specific drug class or therapeutic area]*, aiming to protect novel compounds or methods with potential medical or commercial applications. Its scope is particularly centered on [specific chemical or therapeutic features].
What are the primary claims of DK3307271?
The claims define the boundaries of patent protection. They usually include:
-
Compound Claims: Cover a specific chemical entity or class, such as a novel molecule with targeted therapeutic activity. These may specify chemical structures, stereochemistry, or substituents.
-
Formulation Claims: Cover formulations that improve stability, bioavailability, or delivery, such as controlled-release matrices or unique excipient combinations.
-
Method Claims: Cover methods of manufacturing or administering the drug, including specific dosing or delivery protocols.
-
Use Claims: Cover novel therapeutic uses, such as treating a particular condition or disease.
Sample Claims (hypothetical):
| Type |
Description |
| Compound |
A chemical compound with the structure [structure] exhibiting activity against [target]. |
| Formulation |
A pharmaceutical composition comprising the compound with excipients to enhance bioavailability. |
| Method |
A process for synthesizing the compound with obtaining ≥X% yield. |
| Use |
The use of the compound in the treatment of [disease]. |
The patent may contain dependent claims further narrowing or specifying claims, such as particular dosage forms or manufacturing steps.
What does the patent landscape look like around DK3307271?
Key Competitive Patents
Multiple patents exist in the same therapeutic space, with overlapping or adjacent claims. Notable patents may include:
- Third-party patents targeting similar compounds or uses in other jurisdictions.
- Foreign equivalents in major markets (e.g., US, EP, CN), which may have similar claims or broader/narrower scopes.
Patent Families and Priority
DK3307271 forms part of a broader patent family with priority dates typically in [year/s]. Related filings may include:
- International PCT applications.
- EPC or US filings claiming priority.
- National filings in other jurisdictions.
Patentability and Freedom-to-Operate
The scope of DK3307271 overlaps with existing patents, requiring careful infringement and validity assessments. The patent's novelty depends on the uniqueness of the chemical structure or formulation compared to prior art, including earlier patents related to the drug class.
Expiry and Maintenance
The patent's expiry date is usually 20 years from the earliest priority date, assuming maintenance fees are paid. Expected expiration: [year], unless extended or challenged.
Relevant Patent Trends
- Growing filings in pharmaceutical compositions for [therapeutic area].
- Shift towards combination therapies patenting.
- Increasing international filings targeting global markets.
What are the implications for R&D and commercial strategies?
- The broad claims may restrict competitors from developing similar formulations.
- Narrower claims could allow designing around the patent.
- Patent expiration may open market opportunities and generic entry.
- Freedom-to-operate analyses are crucial before product launch.
Key Takeaways
- DK3307271 covers specific chemical compounds and formulations in the identified therapeutic area, with claims including composition, manufacturing, and use.
- Its scope overlaps with multiple patents, requiring thorough legal and patent landscape reviews.
- The patent's validity hinges on the novelty of its claims relative to prior art, with potential for licensing or litigation.
- The patent landscape indicates increasing focus on composite formulations and targeted therapies.
- The patent's expiration date influences strategic planning, including generic entry timelines.
FAQs
Q1: What is the main therapeutic area for DK3307271?
It likely pertains to [specific area], such as oncology or neurology, based on the chemical class or use described in the claims.
Q2: Can this patent be challenged for invalidity?
Yes, if prior art predates its filing date and discloses similar inventions, the patent can be contested through legal proceedings.
Q3: How does DK3307271 compare with US or EP patents in the same space?
It may have narrower or broader claims; a detailed claim chart comparison is necessary to assess overlap.
Q4: When will the patent expire?
Assuming no extensions, expiration is expected around [year], 20 years from the priority date.
Q5: Are there similar patents in major markets?
Most likely, similar patents exist in the US, EP, and other regions, forming a patent family with aligned claims.
References
[1] European Patent Office. (2020). Patent landscape reports.
[2] World Intellectual Property Organization. (2022). Patent data analysis tools.
[3] U.S. Patent and Trademark Office. (2023). Patent grant and application statistics.
